Experience destructive therapy anogenital warts

Cover Page

Abstract


Objective. To assess the efficiency and tolerability of the Mardil Zinc Max, solution for external application, in topical therapy of patients with anogenital warts. Materials and methods. The study involved 58 women and 12 men at the age of 18 to 57 years old, suffering from anogenital warts. the diagnosis was confirmed by identification of human papillomavirus by the polymerase chain reaction in real time. All the patients were treated by the chemical destruction of anogenital warts with the 1.5% solution of zinc chloropropionate in 50% 2-chloropropionic acid (Mardil Zinc Max) by a single application of the solution on the pathological eruptions. The results of treatment were assessed in 2 weeks, in 1, 3, 6 and 9 months after the destructive therapy. Results. In 2 weeks 62 (88.6%) patients showed a clinical cure with complete tissue regeneration in the lesions, in 8 (11,4%) cases in areas of the preparation erosions were visualized in the epithelialization phase, and they completely resolved within 1 week. recurrences of anogenital warts were detected in 1 (1,4%) patient in the observation period up to 3 months and in 2 (2,8%) patients during 9 months after carrying out the destruction. Adverse drug events have not been identified in the course of therapy and follow-up. Conclusions. As a result of the treatment of anogenital warts with the Mardil Zinc Max high rate of performance and security was set (100%), as well as the low percentage (4,2%) of development of relapses.

About the authors

M. R. Rahmatulina

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: noemail@neicon.ru

Russian Federation

I. A. Nechaeva

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: i.nechaeva76@yandex.ru

Russian Federation

Mardi Shalva

The Cabinet of Dr. Shalva Mardi

Email: noemail@neicon.ru

Russian Federation

References

  1. Mendes D., Bains I., Vanni T., Jit M. Systematic review of model-based cervical screening evaluations. BMC Cancer 2015 May; 1: 315-334.
  2. Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., Koliopoulos G., Naucler P., Sankaranarayanan R., Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012 Nov; 20: 30 (5): 88-99.
  3. Cuzick J., Bergeron C., von Knebel Doeberitz M., Gravitt P., Jeronimo J., Lorincz A.T., J L M Meijer C., Sankaranarayanan R., J F Snijders P., Szarewski A. New technologies and procedures for cervical cancer screening. Vaccine 2012 Nov; 20; 30 (5): 107-116.
  4. Goldie S.J., Kim J.J., Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine 2006 Aug; 31; 24 (3): 164-170.
  5. Del Mistro A. HPV genotyping in the prevention of cervical cancer - how and when can it be a useful marker? Cancer Epidemiol Biomarkers Prev 2015 Jun; 18.
  6. Cheng S., Hua Y., Mu X., Liu C. Infection status of cervical human papilloma virus in patients with cervical intraepithelial neoplasia. Zhonghua Yi Xue Za Zhi 2015 Mar; 24; 95 (11): 857-859.
  7. Tavares M.C., de Lima Junior S.F., Coelho A.V., Marques T.R., de Araujo D.H., Heraclio S.A., Amorim M.M., de Souza P.R., Crovella S. Ann Hum Biol 2015 Jun; 16: 1-8.
  8. Prabhavathy D., Subramanian C.K., Karunagaran D. Re-expression of HPV16 E2 in SiHa (human cervical cancer) cells potentiates NF-kB activation induced by TNF-a concurrently increasing senescence and survival. Biosci Rep 2015 Feb; 25; 35 (1).
  9. Kim K.Y., Blatt L., Taylor M.W. The effects of interferon on the expression of human papillomavirus oncogenes. J Gen Virol 2000 Mar; 81 (Pt 3): 695-700.
  10. Aguilar-Martinez E., Morrisroe C., Sharrocks A.D. The ubiquitin ligase UBE3A dampens ERK pathway signalling in HPV E6 transformed HeLa cells. PLoS One 2015 Mar; 27; 10 (3).
  11. Holloway A., Simmonds M., Azad A., Fox J.L., Storey A. Resistance to UV-induced apoptosis by ß-HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase. Int J Cancer 2015 Jun; 15; 136 (12): 2831-2843.
  12. Jing K., Shin S., Jeong S., Kim S., Song K.S., Park J.H., Heo J.Y., Seo K.S., Park S.K., Kweon G.R., Wu T., Park J.I., Lim K. Docosahexaenoic acid induces the degradation of HPV E6/E7 oncoproteins by activating the ubiquitin-proteasome system. Cell Death Dis 2014 Nov; 13; 5: 1524.
  13. Rob F., Kruzicova Z., Vanousova D., Hercogova J. Condylomata acuminata (genital warts). Ceska Gynekol 2014 Fall; 79 (5): 399-406.
  14. Steben M., Garland S.M. Genital warts. Best Pract Res Clin Obstet Gynaecol 2014 Oct; 28 (7): 1063-73.
  15. Richards S. An overview of genital warts. Nurs Stand 2014 Feb; 12-18; 28 (24): 46-50.
  16. Huang J., Zeng Q., Zuo C., Yang S., Xiang Y., Lu J., Kang J., Tan L., Yu X., Xi C., Huang J., Kang L., Fan F., Chen J. The combination of CO2 laser vaporation and photodynamic therapy in treatment of condylomata acuminata. Photodiagnosis Photodyn Ther 2014 Jun; 11 (2): 130-133.
  17. Lopez-Lopez D., Agrasar-Cruz C., Bautista-Casasnovas A., Älvarez-Castro C.J. Application of cantharidin, podophyllotoxin, and salicylic acid in recalcitrant plantar warts. A preliminary study. Gac Med Mex 2015 Jan-Feb; 151 (1): 14-19.

Statistics

Views

Abstract - 723

PDF (Russian) - 339

PlumX

Dimensions


Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies